ACADIA Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ACADIA Pharmaceuticals generated cash of $16,702,000, which is more than the previous year. Cash used in financing activities reached the amount of $25,129,000 last year. Net change in cash is therefore $73,811,000.
Cash Flow
| 2014 | -66.43M | -87.27M | 203.85M |
|---|---|---|---|
| 2015 | -121.79M | 147.57M | 14.50M |
| 2016 | -210.40M | -261.92M | 533.81M |
| 2017 | -217.85M | 92.47M | 31.18M |
| 2018 | -167.47M | -71.48M | 306.64M |
| 2019 | -151.13M | -165.83M | 371.84M |
| 2020 | -136.16M | 192.50M | 80.99M |
| 2021 | -125.66M | -71.10M | 18.16M |
| 2022 | -114.03M | 73.24M | 8.19M |
| 2023 | 16.70M | 31.99M | 25.12M |
ACAD Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 114.84M | 153.20M | 331.79M | 194.46M | 139.58M | 71.89M | 163.62M | 102.13M | 61.85M | 11.70M |
Operating activities | ||||||||||
Net income | -61.28M | -215.97M | -167.87M | -281.58M | -235.25M | -245.19M | -289.40M | -271.39M | -164.44M | -92.47M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 5.55M | 2.02M | 3.34M | 2.93M | 2.76M | 3.00M | 2.71M | 1.82M | 647K | 206K |
Stock-based compensation expense | 66.42M | 68.20M | 63.61M | 84.42M | 82.26M | 0 | 75.53M | 55.26M | 40.19M | 16.03M |
| Deferred income tax benefit | 66.42M | 68.20M | 63.61M | 84.42M | 82.26M | 0 | 75.53M | 55.26M | 40.19M | 16.03M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -39.27M | 2.17M | -16.11M | -12.46M | -9.69M | -8.74M | -11.44M | -5.90M | -674K | 0 |
Inventories | -28.80M | 2.41M | -4.21M | -3.32M | -1.73M | 1.92M | -1.01M | -3.30M | 0 | 0 |
Accounts payable | 4.79M | 5.87M | -1.61M | 1.27M | 4.05M | -5.61M | 4.87M | 2.24M | -344K | 1.64M |
Cash generated by operating activities | 16.70M | -114.03M | -125.66M | -136.16M | -151.13M | -167.47M | -217.85M | -210.40M | -121.79M | -66.43M |
Investing activities | ||||||||||
Purchases Of Investments | -369.98M | -363.17M | -492.79M | -339.90M | -578.63M | -331.06M | -478.81M | -683.35M | -269.48M | -335.36M |
Investments In Property Plant And Equipment | -40.05M | 0 | -1.12M | -7.58M | -1.12M | -2.14M | -812K | -9.50M | -2.14M | -180K |
Acquisitions Net | -32.04M | 0 | 69.98M | -200.09M | 164.70M | 0 | 0 | 8M | -2.06M | 0 |
Cash generated by investing activities | 31.99M | 73.24M | -71.10M | 192.50M | -165.83M | -71.48M | 92.47M | -261.92M | 147.57M | -87.27M |
Financing activities | ||||||||||
Common Stock Issued | 25.12M | 8.19M | 18.16M | 80.99M | 371.84M | 306.64M | 31.18M | 518.89M | 14.54M | 203.85M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 25.12M | 8.19M | 18.16M | 80.99M | 371.84M | 306.64M | 31.18M | 533.81M | 14.50M | 203.85M |
Net Change In Cash | 73.81M | -32.58M | -178.59M | 137.33M | 54.88M | 67.69M | -94.20M | 61.48M | 40.28M | 50.14M |
Cash at end of period | 188.65M | 120.61M | 153.20M | 331.79M | 194.46M | 139.58M | 69.41M | 163.62M | 102.13M | 61.85M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |